Compare DOGZ & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOGZ | NYXH |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | China | Belgium |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 161.9M |
| IPO Year | 2017 | 2021 |
| Metric | DOGZ | NYXH |
|---|---|---|
| Price | $1.08 | $1.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 57.2K | ★ 308.3K |
| Earning Date | 04-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $1.26 |
| 52 Week High | $16.59 | $8.59 |
| Indicator | DOGZ | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 37.52 | 40.87 |
| Support Level | $0.81 | $1.26 |
| Resistance Level | $1.47 | $3.36 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 15.20 | 57.14 |
Dogness (International) Corp designs, manufactures pet products, including leashes and smart products, and lanyards. The company designs, processes, and manufactures fashionable and high-quality leashes, collars, and harnesses to complement cats' and dogs' appearances, as well as intelligent pet products. The company also provides dyeing services to external customers, as well as pet grooming services. The dyeing service is to utilize the existing production capacity and the pet grooming service is immaterial. Geographically, it generates maximum revenue from Mainland China and also has a presence in the United States, Europe, Australia, Canada, Central, and South America, Japan, and other Asian countries and regions.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.